Showing results (1311-1320 of 1,380) with videos related to

Sort By:
Pageof 138
Bioorganic & Medicinal Chemistry Letters|November 27, 2007
Design and identification of selective HER-2 sheddase inhibitors via P1' manipulation and unconventional P2' perturbations to induce a molecular metamorphosisWenqing Yao, Jincong Zhuo, David M Burns, et al.
Journal of Clinical Apheresis|December 11, 2025
A Web-Based Calculator for Hematopoietic Progenitor Cell Collections: App Development and Retrospective AssessmentMaxwell T Roth, Jun Liu, Sanjana B Shah, et al.
JAMA Cardiology|July 21, 2016
Development and Validation of Risk Prediction Models for Cardiovascular Events in Black Adults: The Jackson Heart Study CohortErvin R Fox, Tandaw E Samdarshi, Solomon K Musani, et al.
Plos One|June 22, 2018
Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignanciesHolly Koblish, Yun-Long Li, Niu Shin, et al.
ACS Medicinal Chemistry Letters|June 18, 2025
Discovery of INCB126503 as a Potent and Selective FGFR2/3 InhibitorMinh H Nguyen, Anlai Wang, Lisa Truong, et al.
Nature Neuroscience|May 18, 2010
DeltaFosB in brain reward circuits mediates resilience to stress and antidepressant responsesVincent Vialou, Alfred J Robison, Quincey C Laplant, et al.
Bioorganic & Medicinal Chemistry Letters|November 2, 2010
Discovery of INCB3344, a potent, selective and orally bioavailable antagonist of human and murine CCR2Chu-Biao Xue, Anlai Wang, David Meloni, et al.
Plos One|April 22, 2020
INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor modelsPhillip C C Liu, Holly Koblish, Liangxing Wu, et al.
ACS Medicinal Chemistry Letters|March 16, 2023
Discovery of Orally Bioavailable FGFR2/FGFR3 Dual Inhibitors via Structure-Guided Scaffold Repurposing ApproachMinh H Nguyen, Hai-Fen Ye, Yao Xu, et al.
Bioorganic & Medicinal Chemistry Letters|June 18, 2002
CCR3 antagonists: a potential new therapy for the treatment of asthma. Discovery and structure-activity relationshipsDean A Wacker, Joseph B Santella, Daniel S Gardner, et al.
Pageof 138